Shock, Cardiogenic Clinical Trials
2 recruiting trials for Shock, Cardiogenic. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Shock, Cardiogenic clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 4: 1.
Research is led by 4TEEN4 Pharmaceuticals GmbH (1), Ottawa Heart Institute Research Corporation (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is AK1967 (Invobenitug also known as Procizumab) (drug, 1 trial), followed by Placebo, Dobutamine.
Track Shock, Cardiogenic trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care
The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS)....
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e....
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Shock, Cardiogenic, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Shock, Cardiogenic, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Shock, Cardiogenic, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.